MannKind Corporation (MNKD) Analysts See $-0.28 EPS

November 7, 2017 - By Jacob Falcon

 MannKind Corporation (MNKD) Analysts See $ 0.28 EPS

Wall Street await MannKind Corporation (NASDAQ:MNKD) to release earnings on November, 8. Analysts forecast EPS of $-0.28, down exactly $1.58 or 121.54 % from 2014’s $1.3 EPS. After posting $-0.35 EPS for the previous quarter, MannKind Corporation’s analysts now forecast -20.00 % EPS growth. About 1.75 million shares traded. MannKind Corporation (NASDAQ:MNKD) has declined 75.27% since November 7, 2016 and is downtrending. It has underperformed by 91.97% the S&P500.

MannKind Corporation (NASDAQ:MNKD) Ratings Coverage

Among 7 analysts covering Mannkind (NASDAQ:MNKD), 2 have Buy rating, 3 Sell and 2 Hold. Therefore 29% are positive. Mannkind has $9 highest and $0.05 lowest target. $3.09’s average target is -5.21% below currents $3.26 stock price. Mannkind had 14 analyst reports since August 3, 2015 according to SRatingsIntel. The stock has “Buy” rating by Maxim Group on Friday, August 11. H.C. Wainwright maintained it with “Buy” rating and $7.0 target in Tuesday, October 24 report. As per Monday, November 16, the company rating was downgraded by Griffin Securities. On Friday, August 28 the stock rating was downgraded by Vetr to “Strong-Buy”. On Wednesday, November 1 the stock rating was downgraded by Maxim Group to “Hold”. The company was downgraded on Wednesday, September 9 by Piper Jaffray. The firm has “Outperform” rating by RBC Capital Markets given on Monday, August 3. Piper Jaffray maintained MannKind Corporation (NASDAQ:MNKD) rating on Wednesday, January 6. Piper Jaffray has “Underweight” rating and $0.05 target. Maxim Group maintained the shares of MNKD in report on Friday, September 1 with “Buy” rating. The company was downgraded on Wednesday, November 4 by RBC Capital Markets.

MannKind Corporation is a biopharmaceutical company. The company has market cap of $374.49 million. The Firm is focused on the discovery and development of therapeutic products for diseases, such as diabetes. It has a 2.41 P/E ratio. The Company’s product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

More notable recent MannKind Corporation (NASDAQ:MNKD) news were published by: Seekingalpha.com which released: “MannKind: Bankruptcy Fears Fade Away” on October 24, 2017, also Seekingalpha.com with their article: “MannKind – Script Sales Dip To Start Q4” published on October 16, 2017, Fool.com published: “Why MannKind Corporation Stock Vaulted Higher in October” on November 06, 2017. More interesting news about MannKind Corporation (NASDAQ:MNKD) were released by: Seekingalpha.com and their article: “MannKind Scripts Rebound – Why The Equity Is Volatile” published on November 06, 2017 as well as Seekingalpha.com‘s news article titled: “MannKind Corporation: Can Afrezza’s Improved Labeling Fuel A Successful Comeback?” with publication date: October 16, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.